A Research Group Finds Most Ovarian Cancers Begin in the Fallopian Tubes. Should They Be Removed?
source: pixabay.com

A Research Group Finds Most Ovarian Cancers Begin in the Fallopian Tubes. Should They Be Removed?

  The Ovarian Cancer Research Alliance stated in new guidance that evidence indicates the majority of ovarian cancers begin in fallopian tubes. The president of the alliance, Audra Moran, was…

Continue Reading A Research Group Finds Most Ovarian Cancers Begin in the Fallopian Tubes. Should They Be Removed?
Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers
source: pixabay.com

Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers

  Dr. Jung-Mo Ahn, associate professor at Dallas University in Texas, created a molecule that kills a broad range of treatment-resistant cancers. The newly targeted group includes triple-negative breast cancer.…

Continue Reading Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers
New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany
source: unsplash.com

New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany

According to a story from Benzinga, the pharmaceutical company Inceptua Group has recently announced that the medicine paclitaxel micellar (marketed as Apealea) is now available in Germany. This medication is…

Continue Reading New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany
ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint
source: pixabay.com

ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint

  Findings from the MITO23 Trial investigating the outcome of the chemotherapy drug trabectedin against physician’s choice to treat BRCA-mutated patients with ovarian cancer were presented at ASCO’s 2022 Annual…

Continue Reading ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint
Compassion Corner: Patient Survives Stage 4 Ovarian Cancer and Credits Her Compassionate Oncologist
source: pixabay.com

Compassion Corner: Patient Survives Stage 4 Ovarian Cancer and Credits Her Compassionate Oncologist

Compassion [kuhm-pash-uhn] noun A feeling of deep sympathy and sorrow for another who is stricken by misfortune, accompanied by a strong desire to alleviate the suffering. Compassion Corner is a…

Continue Reading Compassion Corner: Patient Survives Stage 4 Ovarian Cancer and Credits Her Compassionate Oncologist

Studies Show Favorable Results For PARP Inhibitors in the Treatment of Advanced Ovarian Cancer

Dr. Rachel Grisham MSK ovarian cancer section head discussed clinical trials investigating PARP inhibitors for ovarian cancer patients. The event was a round table discussion and interview for Targeted Oncology.…

Continue Reading Studies Show Favorable Results For PARP Inhibitors in the Treatment of Advanced Ovarian Cancer
6 Myths About Ovarian Cancer Debunked
https://pixabay.com/en/magnifier-glass-magnifying-glass-1714172/

6 Myths About Ovarian Cancer Debunked

Misconceptions exist about many rare diseases. In fact, the efforts of many advocates are focused on education and dispelling these myths. Recently, an article in the Hindustan Times did just…

Continue Reading 6 Myths About Ovarian Cancer Debunked